為達最佳瀏覽效果,建議使用 Chrome、Firefox 或 Microsoft Edge 的瀏覽器。

請至Edge官網下載 請至FireFox官網下載 請至Google官網下載
晴時多雲

    限制級
    您即將進入之新聞內容 需滿18歲 方可瀏覽。
    根據「電腦網路內容分級處理辦法」修正條文第六條第三款規定,已於網站首頁或各該限制級網頁,依台灣網站分級推廣基金會規定作標示。 台灣網站分級推廣基金會(TICRF)網站:http://www.ticrf.org.tw

    《TAIPEI TIMES》 Taiwanese enterovirus vaccine trials successful

    National Taiwan University Children’s Hospital superintendent Huang Li-min, second left, poses for a photograph with the team that successfully completed a phase 3 clinical trial for an enterovirus A71 vaccine in Taipei yesterday.
Photo: Yang Yuan-ting, Taipei Times

    National Taiwan University Children’s Hospital superintendent Huang Li-min, second left, poses for a photograph with the team that successfully completed a phase 3 clinical trial for an enterovirus A71 vaccine in Taipei yesterday. Photo: Yang Yuan-ting, Taipei Times

    2022/05/06 03:00

    By Yang Yuan-ting and Liu Tzu-hsuan / Staff reporter, with staff writer

    National Taiwan University (NTU) Children’s Hospital superintendent Huang Li-min (黃立民) yesterday said a development team he led has successfully completed a phase 3 clinical trial for an enterovirus A71 vaccine in infants aged two months to six years.

    The study has been published in the Lancet medical journal, he said, adding that the vaccine might be approved by the Food and Drug Administration by the end of the year.

    With an efficacy rate of 96.8 percent, the vaccine is a significant improvement over one developed in China that can only be used on infants over six months of age, Huang said.

    A large outbreak of enterovirus in 1998 struck Taiwan, resulting in tens of thousands of children being infected. There were 400 severe cases and 78 deaths.

    Enterovirus 71 (EV71), which caused the 1998 epidemic, causes severe symptoms and can be deadly, affecting young children’s nervous systems, potentially causing brain stem encephalitis or paralysis.

    The international, multi-central, double-blinded phase 3 trials were conducted with 3,061 participants ranging from two months old to six years old, who were divided into three groups: infants aged two months to six months; children aged six months to two years; and children aged two years to six years, Huang said.

    The first two groups received three doses while the final group received two.

    The results showed that 100 percent of the participants who received Taiwan’s enterovirus A71 vaccine did not develop an infection.

    In comparison, 22 participants in the placebo groups developed an enterovirus infection; 11 with EV71 B5 subgenotype and 10 with EV71 C4 subgenotype, showing that the vaccine developed using the B4 subgenotype offered good protection.

    None of the participants had adverse reactions after receiving the vaccine, which can also be administered with other children’s vaccines, the study showed.

    NTU Hospital pediatrician Chang Luan-yin (張鑾英), who participated in the research, said that although the vaccine is highly effective, full vaccination coverage is likely needed to prevent the virus from spreading.

    The team is to track whether antibodies remain in vaccinated participants when they reach age five, Huang said.

    Children over the age of five have mature immune systems that protect against severe symptoms with enterovirus infections, he said.

    For children under the age of two months, researchers might investigate whether vaccinating a pregnant woman could provide antibodies to a fetus, Huang said.

    If the vaccine is approved, the self-paid price could be between NT$2,000 and NT$3,000, he added.

    新聞來源:TAIPEI TIMES

    不用抽 不用搶 現在用APP看新聞 保證天天中獎  點我下載APP  按我看活動辦法

    焦點今日熱門

    網友回應

    此網頁已閒置超過5分鐘,請點擊透明黑底或右下角 X 鈕。